ABOUT US
We are a precision oncology company targeting virus-associated malignancies. Our proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy, Nana-Val, in a pivotal Phase 2 clinical trial for Epstein-Barr virus-positive (EBV+) lymphoma and a Phase 1b/2 trial in patients with advanced EBV+ nasopharyngeal carcinoma and other EBV+ solid tumors. We are also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.
This year we are poised to deliver a steady cadence of anticipated milestones with updates from NAVAL-1 and a preliminary efficacy data from our advanced EBV+ solid tumor study expected in the second half of the year. We look forward to driving value to patients and shareholders in the years ahead
>250K
new cases of EBV-associated cancers each year
>90%
world’s population asymptomatically infected with EBV
